Managing bone metastases and reducing skeletal related events in prostate cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Managing bone metastases and reducing skeletal related events in prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 11, Issue 6, Pages 335-345
Publisher
Springer Nature
Online
2014-05-13
DOI
10.1038/nrclinonc.2014.70
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
- (2013) C de la Piedra et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
- (2013) Jinlu Dai et al. CLINICAL CANCER RESEARCH
- Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2013) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
- (2013) David I Quinn et al. LANCET ONCOLOGY
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
- (2013) John C Araujo et al. LANCET ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients
- (2013) L A Kachnic et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
- (2012) Joel B. Nelson et al. CANCER
- Skeletal-related Events and Clinical Outcomes in Patients with Bone Metastases and Normal Levels of Osteolysis: Exploratory Analyses
- (2012) A. Lipton et al. CLINICAL ONCOLOGY
- A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study
- (2012) Laurence H. Klotz et al. EUROPEAN UROLOGY
- Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid
- (2012) Fred Saad et al. EUROPEAN UROLOGY
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2012) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis
- (2012) Sonya J. Snedecor et al. JOURNAL OF MEDICAL ECONOMICS
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States
- (2011) Jennifer L. Beebe-Dimmer et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors
- (2010) N. Simon Tchekmedyian et al. CANCER INVESTIGATION
- Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease
- (2010) H.L. Neville-Webbe et al. EUROPEAN JOURNAL OF CANCER
- Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men
- (2010) Shabbir M.H. Alibhai et al. JOURNAL OF UROLOGY
- Management of osteoporosis in postmenopausal women
- (2010) &NA; MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
- Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
- (2009) Vivek K. Wadhwa et al. BJU INTERNATIONAL
- SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer
- (2009) Fred Saad et al. CANCER TREATMENT REVIEWS
- Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
- (2009) O. Tatarov et al. CLINICAL CANCER RESEARCH
- The Effects of Serum Testosterone, Estradiol, and Sex Hormone Binding Globulin Levels on Fracture Risk in Older Men
- (2009) Erin S. LeBlanc et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2009) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
- (2009) David P Dearnaley et al. LANCET ONCOLOGY
- Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients
- (2009) Giacomo Novara et al. UROLOGIA INTERNATIONALIS
- Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
- (2008) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan
- (2008) C. I. Ripamonti et al. ANNALS OF ONCOLOGY
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
- (2008) Allan Lipton et al. CANCER
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy
- (2008) Susan L. Greenspan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bisphosphonate nephrotoxicity
- (2008) Mark A. Perazella et al. KIDNEY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started